A trivalent Apx-fusion protein delivered by E. coli outer membrane vesicles induce protection against Actinobacillus pleuropneumoniae of serotype 1 and 7 challenge in a murine model | Zendy

Kui Xu | Zendy; Qin Zhao | Zendy; Xintian Wen | Zendy; Rui Wu | Zendy; Yiping Wen | Zendy; Xiaobo Huang | Zendy; Yong Huang | Zendy; Qigui Yan | Zendy; Xinfeng Han | Zendy; Xiaoping Ma | Zendy; YungFu Chang | Zendy; Sanjie Cao | Zendy

Open Access

A trivalent Apx-fusion protein delivered by E. coli outer membrane vesicles induce protection against Actinobacillus pleuropneumoniae of serotype 1 and 7 challenge in a murine model

Author(s) -

Kui Xu,

Qin Zhao,

Xintian Wen,

Rui Wu,

Yiping Wen,

Xiaobo Huang,

Yong Huang,

Qigui Yan,

Xinfeng Han,

Xiaoping Ma,

YungFu Chang,

Sanjie Cao

Publication year - 2018

Publication title -

plos one

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.99

H-Index - 332

ISSN - 1932-6203

DOI - 10.1371/journal.pone.0191286

Subject(s) - actinobacillus pleuropneumoniae , serotype , microbiology and biotechnology , immune system , bacterial outer membrane , biology , splenocyte , immunity , actinobacillus , pleuropneumonia , virology , immunology , bacteria , escherichia coli , biochemistry , gene , genetics

Actinobacillus pleuropneumoniae (APP) causes serious economic losses in the swine industry, and is the etiologic agent of porcine pleuropneumonia. In this study we have engineered a trivalent Apx fusion protein enclosed in outer membrane vesicles (Apxr-OMV) and studied its immunoprotective efficacy against APP serotypes 1 and 7 challenge in mice. The results showed that the IgG levels in the Apxr-OMVs immune group were significantly higher than those of the negative control ( P < 0.05). Up-regulation of both Th1 (IFN-γ, IL-2) and Th2 (IL-4) cytokines were detected in splenocytes of Apxr-OMVs immune group. The survival rates 87.5% and 62.5% were observed against APP strain 1516 of serotype 7 and APP strain 2701 of serotype 1 in the groups of Apxr-OMVs immune group, respectively. Histopathological lesions of the pulmonary structure alveoli were found to be minimal in APX-OMV group challenged with APP serotypes 1 and 7. These results strongly indicated that engineered OMVs could effectively induce specific humoral or cellular immune responses. Moreover, Apxr-OMVs used as novel vaccine provides cross-protective immunity against different serotype 1 and 7 of APP infection in a mouse model. In contrast, the OMV-empty and PBS as negative controls or inactivated strain of APP-2701 and APP-1516 as positive controls for the animal study cannot provide protection or cross-protection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research